Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
Glaucoma is a group of eye conditions that can damage the optic nerve of the eye, which carries visual information from the eye to the brain. Glaucoma is the leading cause of preventable blindness in the United States. This potentially blinding eye disease currently affects 2.7 million people nationwide. Recent projections from the National Eye Institute (NEI) suggest this number of glaucoma cases will more than double by 2030 .